Conceivably, patients with more profound remissions after treatment have a smaller pool of residual CLL cells from which chemoresistant subclones harboring p53 pathway defects could arise or become enriched, and are therefore less likely to relapse. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.